Chapters

Transcript

Video

What percentage of the overall participants in CAHtalyst demonstrated improvement in either the glucocorticoid dosing or the androstenedione lowering end point?

What percentage of the overall participants in CAHtalyst demonstrated improvement in either the glucocorticoid dosing or the androstenedione lowering end point?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Richard Auchus, MD, PhD

Richard Auchus, MD, PhD

Professor of Pharmacology and Internal Medicine
Division of Metabolism, Endocrinology, and Diabetes
University of Michigan School of Medicine
Ann Arbor, Michigan